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has increasingly focused on the critical role of preventing
thrombus formation by pharmacologically inhibiting coag-
ulation factors and platelets. From a perioperative perspec-
tive this is important because patients undergoing cardiac
surgery often receive multiple antithrombotic and antiplate-
let agents preoperatively that pose important considerations
for management.1 Recently, several novel oral anticoagula-
tion agents (NOACs) have been approved, including dabi-
gatran, a direct thrombin inhibitor, and rivaroxaban,
apixaban, and edoxaban, direct Factor Xa inhibitors that
have multiple indications for either stroke prevention with
nonvalvular atrial fibrillation or thromboprophylaxis.2,3 In
this month’s issue of the Journal, Kaneko4 reviews the peri-
operative considerations of NOACs. Important consider-
ations and perspectives are as follows.
Unlike warfarin, NOACs have rapid and predictable on-
sets, and an offset more rapid than warfarin. Although
monitoring is not required, all of these agents can be evalu-
ated if needed, as Kaneko4 describes. For dabigatran, partial
thromboplastin time can be used but thrombin times or a
specific assay called Hemoclot assay (Aniara,West Chester,
Ohio) should be considered for elective surgery. Rivaroxa-
ban, apixiban, and other Xa inhibitors require specific
calibrated antifactor-Xa assays similar to low-molecular-
weight heparin (LMWH) monitoring. Although concerns
exist regarding the NOACs, managing the condition of
any patient undergoing anticoagulant treatment in a periop-
erative setting can be challenging, because all anticoagula-
tion agents can cause bleeding, and anticoagulation is for a
specific prothrombotic issue. With any anticoagulant there
are important considerations when they require surgery.
Despite growing concerns about NOACs, warfarin man-
agement still perplexes many clinicians because it is not
completely reversible with standard therapies. Despite the
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ded in recent guidelines, and have only recently become
available in the United States.5,6 Unlike warfarin, NOACs
have a direct effect on specific anticoagulation factors,
and their effects normalize in 24 to 48 hours after
discontinuing the drug with normal renal function.
The major concern for clinicians is for emergency proce-
dures or major bleeding. Importantly, there is perceived
concern about the lack of a suitable antidote for these
agents. However, LMWH, a ubiquitous anticoagulant in
hospital settings, does not have an antidote and can cause
major bleeding. However, there is increasing information
available to facilitate managing patients receiving NOACs.3
Important management of NOACs includes discontinu-
ing use, but if reversal is required, specific therapeutic
approaches should be considered, such as the application
of PCCs for reversal and/or bleeding. PCCs in the United
States are available as 4-component or 3-component
products. The 3-component PCCs are deficient in factor
VII. We have reported the ability of PCCs to reverse
rivaroxaban anticoagulation and there are increasing
reports on their off-label use in bleeding cardiac surgical
patients.7-9
There are other important considerations when managing
patients receiving NOACs. When patients bleed, there is
variable correlation between laboratory tests and clinical
bleeding.10 For example, in patients who have a lupus
anticoagulant, coagulation tests are prolonged but in fact
these patients are potentially hypercoagulable. Further,
coagulation tests can be corrected without correcting the
underlying hemostatic defect; we have reported data
where recombinant Factor VIIa corrects the international
normalized ratio of warfarin but only PCCs restore
thrombin generation.11 The lack of correlation between
in vivo bleeding and coagulation assay response was also
observed in a recent trial comparing 4-factor PCC with
plasma in patients treated with vitamin K antagonists with
major bleeding.12
What are the important perspectives for cardiac sur-
geons? It is highly unlikely that NOACs will ever replace
warfarin for prosthetic valve or device anticoagulation
because of the extensive experience using warfarin in this
setting and the multiple targets of warfarin anticoagulation,
including Factors II (prothrombin), VII, IX, and X. When
managing patients taking NOACs who are bleeding or un-
dergoing emergency surgery, a multimodal therapeutic
plan should be considered and established a priori.3,13 In
patients treated with dabigatran, hemodialysis may be a
potential option that could be performed duringgery c November 2014
Levy Editorial Commentarycardiopulmonary bypass.14 The off-label use of PCCs
should be considered when treating bleeding when it occurs
in patients treated with NOACs and includes normalization
of hemostasis with factor concentrates and transfusion
factors.3
Despite concerns about NOACs and bleeding, most
studies suggest patients fare better on NOACs compared
with warfarin.15 In 1 study of 27,419 patients treated up
to 3 years, 1034 patients had 1121 major bleeds. The
30-day mortality after the first major bleed was 9.1% in
the dabigatran group compared with 13.0% in the warfarin
group, and patients treated with dabigatran required a
shorter intensive care unit stay compared with those treated
with warfarin.15 Despite the relative safety of NOACs
compared with warfarin, additional clinical studies are
needed and are underway to determine optimal therapeutic
approaches for bleeding when it occurs. For dabigatran, the
Study of the Reversal Effects of Idarucizumab on Active
Dabigatran is underway.16,17 Another novel agent for Xa
inhibitor reversal that will also reverse LMWH is
Andexanet alpha, which is also in clinical trials for
rivaroxaban and apixiban reversal.18References
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